TransCode Therapeutics (RNAZ) Competitors $13.52 -0.63 (-4.45%) Closing price 04:00 PM EasternExtended Trading$13.40 -0.12 (-0.89%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. KLTO, IMA, TENX, SCYX, ALVR, ITRM, PYRGF, AKTX, DARE, and CVKDShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Klotho Neurosciences (KLTO), ImageneBio (IMA), Tenax Therapeutics (TENX), SCYNEXIS (SCYX), AlloVir (ALVR), Iterum Therapeutics (ITRM), PyroGenesis Canada (PYRGF), Akari Therapeutics (AKTX), Dare Bioscience (DARE), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Klotho Neurosciences ImageneBio Tenax Therapeutics SCYNEXIS AlloVir Iterum Therapeutics PyroGenesis Canada Akari Therapeutics Dare Bioscience Cadrenal Therapeutics Klotho Neurosciences (NASDAQ:KLTO) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Which has higher valuation and earnings, KLTO or RNAZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.45-1.37TransCode TherapeuticsN/AN/A-$16.75MN/AN/A Do insiders and institutionals believe in KLTO or RNAZ? 20.1% of Klotho Neurosciences shares are owned by institutional investors. 26.7% of Klotho Neurosciences shares are owned by insiders. Comparatively, 0.0% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer KLTO or RNAZ? TransCode Therapeutics has a consensus price target of $280.00, indicating a potential upside of 1,971.01%. Given TransCode Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, KLTO or RNAZ? Klotho Neurosciences has a beta of 10.05, indicating that its share price is 905% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Does the media prefer KLTO or RNAZ? In the previous week, TransCode Therapeutics had 7 more articles in the media than Klotho Neurosciences. MarketBeat recorded 10 mentions for TransCode Therapeutics and 3 mentions for Klotho Neurosciences. Klotho Neurosciences' average media sentiment score of 0.64 beat TransCode Therapeutics' score of 0.37 indicating that Klotho Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Klotho Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransCode Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is KLTO or RNAZ more profitable? Klotho Neurosciences' return on equity of -325.88% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -325.88% -242.15% TransCode Therapeutics N/A -378.30%-186.01% SummaryKlotho Neurosciences beats TransCode Therapeutics on 6 of the 11 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.22M$2.62B$6.04B$10.44BDividend YieldN/A57.77%5.73%4.79%P/E RatioN/A22.5785.3127.07Price / SalesN/A637.36588.57190.17Price / CashN/A25.7125.7330.17Price / Book-0.255.3212.666.69Net Income-$16.75M$32.98M$3.31B$276.03M7 Day Performance14.58%0.94%-0.44%-1.13%1 Month Performance24.49%9.70%8.70%6.49%1 Year Performance-99.94%-0.42%76.70%34.41% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.1616 of 5 stars$13.52-4.5%$280.00+1,971.0%-99.9%$11.22MN/A0.009KLTOKlotho Neurosciences1.0613 of 5 stars$0.52+5.8%N/A+12.7%$34.58MN/A-1.16N/AGap UpIMAImageneBio3.3307 of 5 stars$8.61+0.1%$35.50+312.3%-61.4%$34.45M$9.16M-1.1270Positive NewsHigh Trading VolumeTENXTenax Therapeutics2.8051 of 5 stars$7.66+2.1%$18.00+135.0%+121.2%$34.22MN/A-8.339SCYXSCYNEXIS0.6161 of 5 stars$0.79-1.5%N/A-49.7%$33.54M$3.75M-1.9760Gap UpALVRAlloVirN/A$6.64-6.3%N/A-77.0%$33.49MN/A-0.33110News CoverageHigh Trading VolumeITRMIterum Therapeutics2.0851 of 5 stars$0.70+4.4%$9.00+1,185.7%-20.2%$31.64MN/A-0.8210Gap UpPYRGFPyroGenesis Canada0.0683 of 5 stars$0.19+11.5%N/A-69.8%$31.45M$9.14M-3.1290News CoverageGap DownHigh Trading VolumeAKTXAkari Therapeutics2.7972 of 5 stars$1.03+11.9%$3.30+222.0%-65.6%$29.88MN/A0.009DAREDare Bioscience1.8069 of 5 stars$2.25+3.2%$10.00+344.4%-36.7%$29.39M$10K-1.0530News CoveragePositive NewsGap UpHigh Trading VolumeCVKDCadrenal Therapeutics2.5603 of 5 stars$13.53-4.6%$32.00+136.5%+0.9%$29.02MN/A-1.524 Related Companies and Tools Related Companies Klotho Neurosciences Competitors ImageneBio Competitors Tenax Therapeutics Competitors SCYNEXIS Competitors AlloVir Competitors Iterum Therapeutics Competitors PyroGenesis Canada Competitors Akari Therapeutics Competitors Dare Bioscience Competitors Cadrenal Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
